Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 1.00 |
| ▸ | LCK | P06239 | 14/20 | 1.00 |
| ▸ | TEK | Q02763 | 13/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 5/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | CSK | P41240 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920993 | 1.00 | SRC (1.00) | SRCLCKTEKKDREGFR | |
| SCHEMBL23834505 | 0.99 | SRC (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL24458610 | 0.98 | SRC (0.96) | SRCLCKTEKKDREGFR | |
| SCHEMBL16752438 | 0.91 | SRC (0.84) | SRCLCKTEKKDREGFR | |
| SCHEMBL6458490 | 0.91 | LCK (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL6458486 | 0.91 | LCK (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL6460765 | 0.91 | LCK (0.98) | SRCLCKTEKKDREGFR | |
| SCHEMBL7004447 | 0.90 | LCK (1.00) | SRCLCKTEKKDREGFR | |
| SCHEMBL6466052 | 0.90 | LCK (1.00) | SRCLCKTEKKDREGFR | |
| SCHEMBL6465227 | 0.90 | SRC (1.00) | SRCLCKTEKKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| WO-2024182413-A1 | THERAPEUTIC METHODS | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-09-06 | — | — | WO | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-2935567-B1 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC CENTRO DE NEUROCIENCIAS E BIOLOGIA MOLECULAR UNIV DE COIMBRA (PT) | 2019-01-30 | — | — | EP | claimed |
| EP-3283466-A1 | KSR ANTAGONISTS | Icahn School of Medicine at Mount Sinai (US) | 2018-02-21 | — | — | EP | claimed |
| WO-2016168704-A1 | KSR ANTAGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-10-20 | — | — | WO | claimed |
| EP-2935567-A2 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC - Centro de Neurociências E Biologia Molecular - Universidade de Coimbra (PT) | 2015-10-28 | — | — | EP | claimed |
| WO-2014097192-A2 | DIFFERENTIATED CELL POPULATION OF ENDOTHELIAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS, COMPOSITION, SYSTEM, KIT AND USES THEREOF | CNC - CENTRO DE NEUROCIÊNCIAS E BIOLOGIA MOLECULAR - UNIVERSIDADE DE COIMBRA (PT) | 2014-06-26 | — | — | WO | claimed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4680215-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES | MDX Management LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20090092566-A1 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | ELC MANAGEMENT LLC | 2009-04-09 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | SRC 10/4885LCK 189/4885TEK 2146/4885 |
| US-20090092566-A1 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | TNNI3K, CHEK1, CHEK2 | SRC 531/4885LCK 283/4885TEK 3246/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | SRC 89/4885LCK 1/4885TEK 199/4885 |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | BRAF, MAP2K1, MOK | SRC 119/4885LCK 692/4885TEK 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.